Artelo Biosciences对外宣布,其针对新型候选药物Art27.13治疗青光眼的2期临床试验,已成功招募并入组了首位患者。
Artelo Biosciences对外宣布,其针对新型候选药物Art27.13治疗青光眼的2期临床试验,已成功招募并入组了首位患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.